Figure S8. Network Meta-Analysis Results of the Effect of Antidiabetic Therapies on Risk of Genital Tract Infections

CANA	3.72 (0.88, 15.62)	2.72 (0.9, 8.17)	1.17 (0.55, 2.49)	6.25 (3.28, 11.91)	16.99 (3.52, 82.08)	10.49 (1.24, 88.76)	8.03 (2.44, 26.39)	3.44 (1.61, 7.35)
0.27 (0.06,1.13)	**DAPA**	0.73 (0.13, 4.02)	0.32 (0.07, 1.42)	1.68 (0.38, 7.51)	4.57 (2.39, 8.73)	2.82 (0.23, 34.43)	2.16 (0.97, 4.82)	0.93 (0.2, 4.37)
0.37 (0.12,1.11)	1.37 (0.25,7.52)	**EMPA/LINA**	0.43 (0.19, 0.96)	2.3 (0.9, 5.89)	6.25 (1.01, 38.7)	3.86 (0.48, 30.8)	2.95 (0.66, 13.28)	1.27 (0.37, 4.36)
0.85 (0.4,1.81)	3.17 (0.7,14.24)	2.32 (1.04,5.17)	**EMPA**	5.33 (3.27, 8.67)	14.48 (2.82, 74.39)	8.94 (1.21, 65.97)	6.84 (1.92,2 4.37)	2.93 (1.15, 7.5)
0.16 (0.08,0.3)	0.59 (0.13,2.65)	0.43 (0.17,1.11)	0.19 (0.12,0.31)	**GLIM**	2.72 (0.53, 13.86)	1.68 (0.21, 13.13)	1.28 (0.36, 4.53)	0.55 (0.22, 1.36)
0.06 (0.01,0.28)	0.22 (0.11,0.42)	0.16 (0.03,0.99)	0.07 (0.01,0.35)	0.37 (0.07,1.88)	**GLIP**	0.62 (0.05, 8.18)	0.47 (0.17, 1.33)	0.2 (0.04, 1.09)
0.1 (0.01,0.81)	0.35 (0.03,4.32)	0.26 (0.03,2.07)	0.11 (0.02,0.83)	0.6 (0.08,4.67)	1.62 (0.12,21.46)	**LINA**	0.77 (0.07, 8.18)	0.33 (0.04, 2.99)
0.12 (0.04,0.41)	0.46 (0.21,1.03)	0.34 (0.08,1.52)	0.15 (0.04,0.52)	0.78 (0.22,2.75)	2.12 (0.75,5.94)	1.31 (0.12,13.96)	**PLC**	0.43 (0.11, 1.62)
0.29 (0.14,0.62)	1.08 (0.23,5.1)	0.79 (0.23,2.72)	0.34 (0.13,0.87)	1.82 (0.73,4.5)	4.94 (0.92,26.53)	3.05 (0.33,27.76)	2.33 (0.62,8.8)	**SITA**